AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$VKTX

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

Viking Therapeutics (VKTX) fell 2.35% to $25.76, underperforming broader markets. The stock has dropped 36.66% over the past month. The company is expected to report earnings on October 28, 2026, with an estimated EPS of -$1, reflecting a 23.46% decline year-over-year. Full-year estimates project an EPS of -$4.46 and $0 revenue, changes of -39.81% and 0%, respectively. The stock has a Zacks Rank of #2 (Buy).

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$VKTX
Bearish
medium confidence
Mentioned
$VKTX
Relevance
4/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$VKTXBearishLow
01

Why it matters

The preview highlights a continued loss trajectory, which may reinforce bearish sentiment.

02

Market read

Pre-earnings outlook suggests potential downside pressure on VKTX.

03

What to watch

Potential upcoming partnership or pipeline news not covered in the preview.

Relevance 4/10Novelty 3/10Timing: ahead of earnings release on Oct 28

Background

Viking Therapeutics is a biotech firm with a history of losses; the article provides a Zacks Rank and industry ranking.

Company-level read

Ticker impact

$VKTXBearishMedium confidence
Context

The article previews Viking Therapeutics' upcoming earnings on Oct 28, citing a projected EPS of -$1 and recent share decline, indicating potential price impact.

Expected impact

likely downside as market prices in the projected loss

Evidence & confidence

Projected negative EPS and recent share weakness suggest traders may sell ahead of the release.

Market effects

Sector

Medical - Biomedical and Genetics sector may see modest impact from Viking's performance.

Regional

U.S. biotech segment could be slightly affected.

Global

Limited to investors tracking biotech earnings.

Counterpoint

What could challenge this read

If the company beats the negative guidance, the stock could rally sharply.

Key entities

  • company
    Viking Therapeutics, Inc.

    Biotech company subject of the earnings preview.

Read at source← All news

Related articles

OCT 20
$VKTXLowAI 8/10

Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2

Viking Therapeutics (VKTX) has initiated two Phase 3 trials for its oral weight loss drug, VK2735, targeting obesity and type 2 diabetes. The move follows mixed Phase 2 results, with concerns about tolerability. The company aims to improve outcomes with a longer trial duration, reduced tablet size, and lower dosing. Phase 1 data showed good tolerability, but Phase 2 had a 20% discontinuation rate due to adverse events.

finance.yahoo.com2 min
OCT 14
$VKTXMed

Viking Launches Phase 3 SUNRISE Program For Oral Obesity Drug VK2735

Viking Therapeutics (VKTX) began Phase 3 trials for its obesity drug VK2735, testing oral formulations in two 68-week studies with 560 adults each. The trials aim to assess efficacy and safety, with primary endpoints measuring weight change. VK2735 previously showed promising results in a Phase 2 study. The company reported $502M in cash reserves as of June 30, 2026, with its stock trading between $25.77 and $43.15 over the past year.

rttnews.com4 min
OCT 14
$VKTXMedAI 8/10

Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know

Viking Therapeutics (VKTX) has begun Phase 3 trials for its obesity pill, VK2735, competing with Eli Lilly (LLY) and Novo Nordisk (NVO). The company aims to offer both oral and injectable treatments, but regulatory approval depends on trial success. VKTX shares are down 24% this year, underperforming LLY but outperforming NVO. Retail sentiment on Stocktwits is bearish.

finance.yahoo.com1 min
OCT 14
$VKTXMed

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3

Viking Therapeutics (VKTX) has started Phase 3 trials for its oral obesity drug VK2735, targeting adults with and without type 2 diabetes. The SUNRISE-1 and SUNRISE-2 studies will evaluate the drug's efficacy and safety over 68 weeks, with primary endpoints measuring body weight change. Viking aims to expand treatment options for obesity with this once-daily oral therapy, complementing its subcutaneous formulation in Phase 3 trials.

gurufocus.com2 min